retatrutide clinical trials results weight loss First phase 3 data, a Triumph of Science! VisualAbstract: Retatrutide reduces body weight

In two clinical trials, people with obesity who received weight-loss drug Zepbound saw a greater average reduction in sleep apnea events over the course of a year, compared to people who received a non-acting placebo

Every single batch undergoes rigorous testing to verify consistency, safety, and exact ingredient standards

Within 52 weeks, they regained more than 14 percent of body weight on average

This condition requires guided rehabilitation under the supervision of a trained pelvic floor physical therapist

For a deeper look at why dose escalation creates problems long-term, read our post on why higher GLP-1 doses don't always produce better long-term results

Shelby Sullivan, director of the Endoscopic Bariatric and Metabolic Program at Dartmouth Health Weight Center and lead author of the research said